CN100528178C - Application of fatty-acid synthase inhibitor - Google Patents
Application of fatty-acid synthase inhibitor Download PDFInfo
- Publication number
- CN100528178C CN100528178C CNB2005100680542A CN200510068054A CN100528178C CN 100528178 C CN100528178 C CN 100528178C CN B2005100680542 A CNB2005100680542 A CN B2005100680542A CN 200510068054 A CN200510068054 A CN 200510068054A CN 100528178 C CN100528178 C CN 100528178C
- Authority
- CN
- China
- Prior art keywords
- fatty acid
- leaf
- acid synthase
- acer truncatum
- truncatum buge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940123469 Fatty acid synthase inhibitor Drugs 0.000 title claims description 15
- 241000219226 Acer truncatum Species 0.000 claims description 28
- 239000000284 extract Substances 0.000 claims description 16
- 239000012046 mixed solvent Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 238000002386 leaching Methods 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 238000001704 evaporation Methods 0.000 claims description 8
- 230000008020 evaporation Effects 0.000 claims description 8
- 230000006837 decompression Effects 0.000 claims description 7
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 7
- 229930195729 fatty acid Natural products 0.000 abstract description 7
- 239000000194 fatty acid Substances 0.000 abstract description 7
- 102000003960 Ligases Human genes 0.000 abstract description 6
- 108090000364 Ligases Proteins 0.000 abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 2
- 241000305548 Pterocarya stenoptera Species 0.000 abstract 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 abstract 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 21
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 12
- 239000000126 substance Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000010298 pulverizing process Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002024 ethyl acetate extract Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000643 oven drying Methods 0.000 description 3
- GVEZIHKRYBHEFX-MNOVXSKESA-N 13C-Cerulenin Natural products CC=CCC=CCCC(=O)[C@H]1O[C@@H]1C(N)=O GVEZIHKRYBHEFX-MNOVXSKESA-N 0.000 description 2
- 241001143500 Aceraceae Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- GVEZIHKRYBHEFX-UHFFFAOYSA-N caerulein A Natural products CC=CCC=CCCC(=O)C1OC1C(N)=O GVEZIHKRYBHEFX-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- GVEZIHKRYBHEFX-NQQPLRFYSA-N cerulenin Chemical compound C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O GVEZIHKRYBHEFX-NQQPLRFYSA-N 0.000 description 2
- 229950005984 cerulenin Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- LTYOQGRJFJAKNA-IJCONWDESA-N malonyl-coenzyme a Chemical compound O[C@@H]1[C@@H](OP(O)(O)=O)[C@H](CO[P@](O)(=O)O[P@@](O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-IJCONWDESA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 241000219240 Acer pictum subsp. mono Species 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- -1 tetramethyl azo azoles Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A fatty acid synthetase deppressant for preventing and treating the diseases associated with the fatty acid synthetase as target, especially the cancer, is prepared from the leaf of pterocarya stenoptera through extracting in the mixture of water and ethanol (or propanol).
Description
Technical field
The present invention relates to the inhibitor and preparation method thereof and application of enzyme, particularly relate to a kind of fatty acid synthase inhibitor and preparation method thereof and be the prevention of relevant disease of target spot and the application in the auxiliary treatment with the fatty acid synthase, especially relate to a kind of fatty acid synthase inhibitor and preparation method thereof and with its be active component press down cancer and slimming medicine.
Background technology
The former title fatty acid synthetase of fatty acid synthase, (EC 2.3.1.85, fatty acid synthase is abbreviated as FAS), the intravital fatty acid synthase of animal is called I type FAS, and the fatty acid synthase in prokaryote and the plant is called II type FAS.Basic research both at home and abroad shows that fatty acid synthase is the potential target position that can be used for the treatment of purpose.
So far, the fatty acid synthase inhibitor of having reported is less, has only synthetic C75 (Kuhajda F.P., Pizer E.S., Li J.N., et al.Proc Natl Acad Sci USA, 97,3450-3454 (2000)), natural product cerulenin (cerulenin) (Vance D., the Goldberg I. that early finds, Mitsuhashi O.et al.Biochem Biophys Res Commun.48,649-656 (1972)) and the ester catechin EGCG in the green tea (Wang X., Tian W.X..Biochem Biophys Res Commun, 288 (5): 1200-1206 (2001)) and ECG (Wang X., Song K.S., Guo Q.X., et al.Biochem Pharmacol, 66:2039-2047 (2003)).The common drawback that these inhibitor had is to suppress active not high enough, and using value is limited to, and therefore searches out the active high fatty acid synthase inhibitor of inhibition and has important application value.
Acer Truncatum Buge has another name called acer monoes (Acer Truncatum Bunge) and belongs to (AcerLinn) plant for Aceraceae (Aceraceae) maple.
Summary of the invention
The purpose of this invention is to provide a kind of fatty acid synthase inhibitor and preparation method thereof.
Fatty acid synthase inhibitor provided by the present invention is to be raw material with the leaf of Acer Truncatum Buge, obtains with acetone-water or ethanol-water mixed solvent leaching.
The percentage by volume of acetone is 50-70% in the described acetone-water mixed solvent; Alcoholic acid percentage by volume is 50-70% in the described ethanol-water mixed solvent.
The ratio of weight and number of mixed solvent and Acer Truncatum Buge cured leaf is 8-30: 1.
The method of leaching is to stir or reflux under 25-70 ℃ of temperature; The time of stirring leaching is 3-24 hour; The time of reflux is 2-3 hour.
Need after the said extracted to filter, keep filtrate and concentrated; Spissated method is a low-temperature evaporation, and purpose is the organic solvent of removing wherein.
For obtaining better purification effect, also can be to further concentrating with the concentrated working substance that obtains after filtration, method is: extract with ethyl acetate, acetic acid ethyl acetate extract (decompression) low-temperature evaporation is concentrated again, remove organic solvent and obtain through spissated working substance extractum.Further (vacuum) drying of this extractum can be obtained solid matter.
Describedly also can comprise and divide several times to extract, remove lipid material wherein with isopyknic petroleum ether in the further spissated method of working substance extractum.
The strong inhibition composition that contains fatty acid synthase in the leaf of Acer Truncatum Buge, provided by the present invention is the fatty acid synthase inhibitor of feedstock production with the leaf of Acer Truncatum Buge, has higher fatty acid synthase restraining activity, and the leaf of Acer Truncatum Buge with the Various Seasonal collection is the inhibition activity no significant difference of the fatty acid synthase inhibitor of feedstock production to fatty acid synthase, in addition, this fatty acid synthase inhibitor has the effect of stronger inhibition growth to tumor cell.The present invention will be aspect the prevention and auxiliary treatment of relevant disease of target spot with the fatty acid synthase, at preparation controlling body weight, the control medicine with fat relevant aspects such as disease, particularly play a great role in preparing the medicine of preventing curing cancers.Simultaneously, fatty acid synthase inhibitor of the present invention also has bigger using value in the production of health product and cosmetics.
The specific embodiment
Among the following embodiment, used fatty acid synthase is with conventional method (W.X.Tian et al., 1985.J.Biol.Chem., 260 (20): 11375-11387; Tian Weixi etc., body lipid level of 1996. different growing stages laying hens and the active relation of liver fatty acid synthetase. journal of biological chemistry, 12 (2): 234-236) in fresh duck liver, separate to purify, and detect through polyacrylamide gel electrophoresis and to be single band.
Active S-acetyl-coenzyme-A, malonyl coenzyme A, the NADPH of adopting of fatty acid synthase is standard measuring method for activity mensuration (W.X.Tian et al., 1985.J.Biol.Chem., 260 (20): 11375-11387 of substrate; Tian Weixi etc., body lipid level of 1996. different growing stages laying hens and the active relation of liver fatty acid synthetase. journal of biological chemistry, 12 (2): 234-236).
The extraction of active substance in embodiment 1, the leaf of Acer Truncatum Buge
The leaf of Acer Truncatum Buge of gathering in each (comprising fall foliage) is cleaned in season, dry naturally or oven drying at low temperature (＜50 ℃) after with its pulverizing, with following method extraction working substance:
Mixed in 20: 1 by ratio of weight and the number of copies with the Acer Truncatum Buge cured leaf of above-mentioned pulverizing with ethanol-water mixed solvent (alcoholic acid percentage by volume is 70%), room temperature stirs leaching 12 hours down for 25 ℃, filters; Re-leaching is 12 hours under similarity condition, filters then, and twice filtrate is merged, and (decompression) low-temperature evaporation concentrates, and removes organic solvent wherein, obtains active substance extractum, i.e. fatty acid synthase inhibitor.Can further extractum (vacuum) dry (＜55 ℃) be obtained solid matter.
The extraction of active substance in embodiment 2, the leaf of Acer Truncatum Buge
The leaf of Acer Truncatum Buge of gathering in each (comprising fall foliage) is cleaned in season, dry naturally or oven drying at low temperature (＜50 ℃) after with its pulverizing, with following method extraction working substance:
With the acetone-water mixed solvent (percentage by volume of acetone is 60%) and the Acer Truncatum Buge cured leaf of above-mentioned pulverizing is to mix at 20: 1 by ratio of weight and the number of copies, and reflux 3 hours is filtered; Reheat refluxed 2 hours under similarity condition, filter, twice filtrate is merged, (decompression) low-temperature evaporation concentrates, remove organic solvent wherein, obtain the active substance water, can the working substance of aqueous phase further be concentrated, concrete grammar is: divide with isopyknic petroleum ether earlier to extract for 3-4 time, remove lipid material wherein, the reuse ethyl acetate extracts, and acetic acid ethyl acetate extract (decompression) low-temperature evaporation is concentrated, remove organic solvent and obtain, further (vacuum) drying of this extractum can be obtained solid matter through spissated working substance extractum.
The extraction of active substance in embodiment 3, the leaf of Acer Truncatum Buge
The leaf of Acer Truncatum Buge of gathering in each (comprising fall foliage) is cleaned in season, dry naturally or oven drying at low temperature (＜50 ℃) after with its pulverizing, with following method extraction working substance:
With the ethanol-water mixed solvent (ethanol is 60: 40 with the volume parts ratio of water) and the Acer Truncatum Buge cured leaf of above-mentioned pulverizing is to mix at 10: 1 by ratio of weight and the number of copies, reflux 3 hours, filter then, reheat refluxed 2 hours under similarity condition, twice filtrate is merged, (decompression) low-temperature evaporation concentrates, remove organic solvent wherein, obtain containing the water of active substance, can the working substance of aqueous phase further be concentrated, concrete grammar is: extract with ethyl acetate, acetic acid ethyl acetate extract (decompression) low-temperature evaporation is concentrated, remove organic solvent and obtain, further (vacuum) drying of this extractum can be obtained solid matter through spissated working substance extractum.
Embodiment 4, fatty acid synthetase is suppressed active detection
Under 37 ℃, in 2 milliliters of quartz colorimetric utensils, add this zymolyte: 0.2mM S-acetyl-coenzyme-A solution 25 microlitres, 0.4mM malonyl coenzyme A solution 50 microlitres and 1.3mM NADPH solution 50 microlitres, add 0.1M again, pH 7.0 phosphate buffer 1 .85 milliliters and FAS solution 30 microlitre mixings start enzymatic reaction.The vigor of representing FAS with the variation (Δ A/min) of the light absorption value A of 340nm wavelength place in the spectrophotometer monitoring unit interval.In the presence of the finite concentration leaf of Acer Truncatum Buge extract, the vigor of FAS holoenzyme reaction descends, and the concentration of required leaf of Acer Truncatum Buge extract is IC when its vigor drop by half
50, with the inhibition ability of this numeric representation leaf of Acer Truncatum Buge (comprising fall foliage) extract to FAS, the final concentration of FAS is 7 mcg/ml in the above-mentioned survey live body system.
Measurement result shows: under condition is lived in above-mentioned survey, and the IC of leaf of Acer Truncatum Buge extract
50Be 2-3 mcg/ml (slightly variant) that it is heavy to amount to into cured leaf, is the 20-30 mcg/ml with season.
Embodiment 5, tumor cell experiment
Cell culture: esophageal carcinoma CAES-17, gastric cancer BGC-823, breast carcinoma MCF-7 and four kinds of JEG-3 of hepatocarcinoma BEL-7402 (all available from medical courses in general institute institute of materia medica) are incubated in the RPMI-1640 culture fluid that contains 10% calf serum, penicillin (100 μ g/ml) and streptomycin (100 μ g/ml), at suitable humidity, 5%CO
2Incubator in the cultivation of going down to posterity of 37 ℃ of monolayer adherences.
Collect four kinds of tumor cells of exponential phase, be inoculated in 96 orifice plates 2 * 10 respectively
4Individual/hole, adhere-wall culture changed the culture fluid of the Acer Truncatum Buge extract that contains embodiment 1, embodiment 2 and embodiment 3 acquisitions in 24 hours respectively into, be divided into 7 groups by different Acer Truncatum Buge extract concentrations and (establish 0,5,10,20,40,60,80 μ g/mL totally 7 experimental grouies, each concentration is established 3 multiple holes, and experimental result is averaged).
Continue to cultivate 24 hours, change the culture fluid that does not contain extract into, (tetramethyl azo azoles indigo plant 5mg/ml) continues to cultivate 4 hours to add 20 μ L MTT simultaneously.Abandon supernatant, every hole adds 200 μ L dimethyl sulfoxide (DMSO) (matched group adds equivalent culture fluid and dimethyl sulfoxide), and level concussion 10 minutes is fully dissolved crystal.Measure light absorption value (A) with microplate reader, wavelength 570nm, and by the inhibitory action of following formula calculating extract to growth of cancer cells, the result is as shown in table 1, shows that fatty acid of the present invention and enzyme inhibitor have significant inhibitory effect to tumor cell.
Inhibitory rate of cell growth (%)=(1-experimental group A
570/ control group A
570) * 100%
Table 1 variable concentrations extract (acting on 24 hours) is to the suppression ratio (%) of growth of tumour cell
Annotate: but above-mentioned cancer is tested used leaf of Acer Truncatum Buge extract, and the ethyl acetate step is further concentrated, and the extract of Various Seasonal leaf and fall foliage does not have significant difference to the inhibition ability of cancerous cell.
Claims (3)
1, the application of leaf of Acer Truncatum Buge extract in the preparation fatty acid synthase inhibitor, described leaf of Acer Truncatum Buge extract is to be raw material with the leaf of Acer Truncatum Buge, obtains with acetone-water or ethanol-water mixed solvent leaching; The percentage by volume of acetone is 50-70% in the described acetone-water mixed solvent; Alcoholic acid percentage by volume is 50-70% in the described ethanol-water mixed solvent; The ratio of weight and number of described mixed solvent and Acer Truncatum Buge cured leaf is 8-30: 1.
2, the application of fatty acid synthase inhibitor according to claim 1 is characterized in that: the method for described leaching is stirring under 25-70 ℃, or reflux; Described is 3-24 hour 25-70 ℃ of time of stirring leaching down; The time of reflux is 2-3 hour.
3, the application of fatty acid synthase inhibitor according to claim 1 is characterized in that: also filter and concentrate after the described leaching; Described spissated method is the decompression low-temperature evaporation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100680542A CN100528178C (en) | 2005-05-09 | 2005-05-09 | Application of fatty-acid synthase inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100680542A CN100528178C (en) | 2005-05-09 | 2005-05-09 | Application of fatty-acid synthase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1861103A CN1861103A (en) | 2006-11-15 |
| CN100528178C true CN100528178C (en) | 2009-08-19 |
Family
ID=37388689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100680542A Expired - Fee Related CN100528178C (en) | 2005-05-09 | 2005-05-09 | Application of fatty-acid synthase inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100528178C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101768081B (en) * | 2009-01-06 | 2013-03-27 | 首都医科大学 | Inhibitor of fatty acid synthase and application thereof |
| JP2010229062A (en) * | 2009-03-26 | 2010-10-14 | Fancl Corp | Bleaching agent |
| CN105168214B (en) * | 2015-08-11 | 2018-03-13 | 中国科学院西北高原生物研究所 | The new application of benzylisoquinoline alkaloid |
-
2005
- 2005-05-09 CN CNB2005100680542A patent/CN100528178C/en not_active Expired - Fee Related
Non-Patent Citations (6)
| Title |
|---|
| 元宝枫叶总黄酮提取方法研究. 王兰珍，马希汉，王姝清，王性炎.西北林学院学报，第12卷第4期. 1997 |
| 元宝枫叶总黄酮提取方法研究. 王兰珍，马希汉，王姝清，王性炎.西北林学院学报，第12卷第4期. 1997 * |
| 元宝枫的综合开发利用. 李云志，曾凡骏，曾里.食品与发酵工业，第30卷第6期. 2004 |
| 元宝枫的综合开发利用. 李云志，曾凡骏，曾里.食品与发酵工业，第30卷第6期. 2004 * |
| 脂肪酸合成酶抑制剂的抗癌研究. 张晔.国外医学肿瘤学分册，第29卷第4期. 2002 |
| 脂肪酸合成酶抑制剂的抗癌研究. 张晔.国外医学肿瘤学分册，第29卷第4期. 2002 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1861103A (en) | 2006-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sugiura et al. | Isolation of a new anti-allergic phlorotannin, phlorofucofuroeckol-B, from an edible brown alga, Eisenia arborea | |
| Zhang et al. | Induction of HL-60 apoptosis by ethyl acetate extract of Cordyceps sinensis fungal mycelium | |
| CN102861112B (en) | Kosteletzkya virginica lignan extract and preparation method and application thereof | |
| CN104688782A (en) | Method for efficiently extracting triterpene active components from Indian buead peel | |
| CN101747196A (en) | Method for preparing chlorogenic acid by using Jerusalem artichoke | |
| CN105111263B (en) | Flavone compound isolated and purified from shepherd's purse and its production and use | |
| CN100528178C (en) | Application of fatty-acid synthase inhibitor | |
| CN1899331B (en) | Extract of aceraceous plant and its extracting method and use | |
| KR100796303B1 (en) | Manufactruring method of the germiated soybean cordyceps militaris having a bird flu preventing function | |
| CN101768081B (en) | Inhibitor of fatty acid synthase and application thereof | |
| CN102119953A (en) | Application of euphorbia humifusa wild extract | |
| CN105712963B (en) | A kind of coumarin dimer and its preparation method and application | |
| CN109022309B (en) | Stenotrophomonas maltophilia capable of producing free fatty acid and application thereof | |
| CN114146083B (en) | Sophora japonica extract and active ingredient and application thereof in preparation of products for treating glycolipid metabolism comprehensive disorder | |
| Yunarto et al. | Inhibitory activity of Uncaria Gambir Roxb extract, ethyl acetate fraction, and catechin isolate on lipase | |
| CN103408528B (en) | Chroman compound, as well as preparation method and application thereof | |
| CN104593443A (en) | Preparation method of agilawood chromone component | |
| CN104857036B (en) | A kind of extracting method and product of euscaphis konishii active material | |
| CN107382944B (en) | Coumarin gossypol derivatives with anti-tumor activity and synthesis method thereof | |
| Mal'ucka et al. | Free-radical scavenging activities of cultured mycelia of Paecilomyces hepiali (Ascomycetes) extracts and structural characterization of bioactive components by nuclear magnetic resonance spectroscopy | |
| CN104988193A (en) | Production method for 10, 11-dehydrogenated curvularin and application thereof | |
| CN103450142B (en) | Chroman compound as well as extracting method and application thereof | |
| CN110178857A (en) | The purposes of sea-buckthorn endogenetic fungal bacterial strain SJ1 extractive from fermentative | |
| CN114656393B (en) | Pyrrole-2-aldehyde compound and preparation method and application thereof | |
| AU2002227952B2 (en) | Klainetin and derivatives thereof, method for their production and the use of the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090819 Termination date: 20120509 |